Direct comparison of doses did not show evidence of dose dependence for blood pressure-lowering for any of the other thiazides for which RCT data were available : bendrofluazide , chlorthalidone , cyclopenthiazide , metolazone or indapamide .
This is based on an informal indirect comparison of results observed in other Cochrane review s on ACE inhibitors , ARBs and renin inhibitors compared with placebo , which used similar inclusion /exclusion criteria to the present review .Thiazides reduced potassium , increased uric acid and increased total cholesterol and triglycerides .
These effects were dose-related and were least for hydrochlorothiazide .
Chlorthalidone increased serum glucose but the evidence was unclear for other thiazides .
This systematic review shows that hydrochlorothiazide has a dose-related blood pressure-lowering effect .
Thiazides reduced potassium , increased uric acid and increased total cholesterol and triglycerides
BACKGROUND Hypertension is a modifiable cardiovascular risk factor .
Although it is established that low-dose thiazides reduce mortality as well as cardiovascular morbidity , the dose-related effect of thiazides in decreasing blood pressure has not been subject to a rigorous systematic review .
It is not known whether individual drugs within the thiazide diuretic class differ in their blood pressure-lowering effects and adverse effects .
OBJECTIVES To determine the dose-related decrease in systolic and /or diastolic blood pressure due to thiazide diuretics compared with placebo control in the treatment of patients with primary hypertension .
Secondary outcomes included the dose-related adverse events leading to patient withdrawal and adverse biochemical effects on serum potassium , uric acid , creatinine , glucose and lipids .
Randomized Prospective Study of a Nonthiazide Diuretic, Indapamide, in Preventing Calcium Stone Recurrences
We examined the biochemical changes and the efficacy of indapamide in the prevention of  calcium stone recurrences . Seventy-five patients with calcium nephrolithiasis and hypercalciuria were r and omly assigned to three different therapies : diet and fluid ( group A ) , diet and fluid plus indapamide 2.5 mg/day ( group B ) . and diet and fluid plus indapamide 2.5 mg/day plus allopurinol 300 mg/day ( group C ) . Before treatment and after 6 , 12 , 24 , and 36 months of therapy , we evaluated blood pressure , serum and urine risk parameters ( including relative supersaturations of calcium oxalate . calcium phosphate and uric acid ) , stone rate , and the proportion of calculi-free patients .  During the 3 years of treatment , urinary calcium greatly decreased in groups B and C. dropping to 50 % of the pretreatment values : urinary oxalate also significantly declined in group B ( - 24 % ) and group C ( -27 % ) . Relative supersaturations of calcium oxalate and calcium phosphate decreased to the same extent in groups B and C ( about one-half of the pretreatment value ) , and relative supersaturation of uric acid was particularly reduced in group C ( -65 % of the pretreatment value ) . The stone rate improved in all three groups ( p > 0.005 ) . but using actuarial analysis in the evaluation of calculi-free patients , indapamide , and indapamide plus allopurinol groups were found to have a significantly more favorable effect than diet and fluid treatment ( p > 0.02 ) , without any difference between the two drug groups . Because indapamide has fewer side effects than thiazide diuretics , we conclude that indapamide could be an interesting alternative to thiazides in the prevention of calcium stones in hypercalciuric patients
Direct comparison of doses did not show evidence of dose dependence for blood pressure-lowering for any of the other thiazides for which RCT data were available : bendrofluazide , chlorthalidone , cyclopenthiazide , metolazone or indapamide .
This is based on an informal indirect comparison of results observed in other Cochrane review s on ACE inhibitors , ARBs and renin inhibitors compared with placebo , which used similar inclusion /exclusion criteria to the present review .Thiazides reduced potassium , increased uric acid and increased total cholesterol and triglycerides .
These effects were dose-related and were least for hydrochlorothiazide .
Chlorthalidone increased serum glucose but the evidence was unclear for other thiazides .
This systematic review shows that hydrochlorothiazide has a dose-related blood pressure-lowering effect .
Thiazides reduced potassium , increased uric acid and increased total cholesterol and triglycerides
BACKGROUND Hypertension is a modifiable cardiovascular risk factor .
Although it is established that low-dose thiazides reduce mortality as well as cardiovascular morbidity , the dose-related effect of thiazides in decreasing blood pressure has not been subject to a rigorous systematic review .
It is not known whether individual drugs within the thiazide diuretic class differ in their blood pressure-lowering effects and adverse effects .
OBJECTIVES To determine the dose-related decrease in systolic and /or diastolic blood pressure due to thiazide diuretics compared with placebo control in the treatment of patients with primary hypertension .
Secondary outcomes included the dose-related adverse events leading to patient withdrawal and adverse biochemical effects on serum potassium , uric acid , creatinine , glucose and lipids .